Cancer Immunotherapy News and Research

RSS

New cancer vaccine harnesses COVID-19 immune memory to fight tumors

In a discovery that could redefine the future of cancer immunotherapy, scientists from Celloram Inc., University Hospitals and Case Western Reserve University have developed a novel cancer vaccine platform that transforms the impact of the largest immunological event in modern history – a synchronized mass immune memory generated through SARS-CoV-2 infection and vaccination – into a powerful ally against cancer.

27 Jul 2026

MEK inhibition could limit T cell exhaustion and give a boost to immunotherapy

A major pillar of cancer immunotherapy involves stimulating T cells, the specialized killers of the immune system, to attack tumors.

23 Jul 2026

Mass-producible immune cells fight solid human tumors in mice

Off-the-shelf and mass-producible immune cells fight solid human tumors engrafted into mice. The Kobe University development is a significant contribution towards faster and cheaper cancer immunotherapy.

23 Jul 2026

Ancient immune protein C3 boosts cancer immunotherapy within tumors

An ancient molecule that existed long before the blood circulation system evolved, has been found to support cancer immunotherapy.

23 Jul 2026

Thymulin curbs age-related inflammation and slows breast tumors in mice

Thymulin reduced age-associated inflammatory myeloid cells and slowed breast-tumor growth in aged mice by suppressing NF-κB signaling. The peptide also restored anti-PD-L1 responsiveness in aged mouse models, while human cell and tumor data supported an age-linked inflammatory myeloid profile.

23 Jul 2026

Study reveals how p53 mutations cause tumors to resist cancer immunotherapy

Immune checkpoint blockade (ICB) therapy has transformed cancer treatment, but many tumors remain resistant.

22 Jul 2026

UVA researchers develop a new experimental approach to target glioblastoma

University of Virginia Comprehensive Cancer Center scientists have developed a promising new experimental approach to targeting glioblastoma, the most common and deadliest brain cancer.

22 Jul 2026

Unlocking the untapped 90%: Membrane protein purification as a three hours routine workflow

Automated, detergent-free purification preserves native membrane protein structure while supporting more reliable target validation workflows.

From Analytik Jena 21 Jul 2026

Thymus hormone identified as key player in reversing age-related inflammation

Chronic, low-grade inflammation in the body-a phenomenon known as "inflammaging" because it increases with age-has been linked to many of today's leading causes of illness and death, including cancer, heart disease, metabolic conditions and neurodegenerative diseases.

21 Jul 2026

Exercise oncology could unlock new therapeutic pathways against cancer

Regular exercise is associated with improved outcomes for many patients with cancer, yet those with advanced disease may be unable to participate in exercise-based interventions.

20 Jul 2026

Specialized blood vessels enable effective immune defense against cancer metastases

It has long been suspected that endothelial cells, the specialized cells lining the inner walls of blood vessels, play a key role in determining how the body’s immune system responds to tumors.

20 Jul 2026

KAIST study opens a new avenue for treating intractable brain tumors

Researchers have uncovered a clue to why immune checkpoint inhibitors-cancer therapies that release the immune "brakes" exploited by tumors to evade attack-show limited efficacy in some brain tumors.

19 Jul 2026

Targeting ZBP1 may overcome cancer immunotherapy resistance

A new Review published in the open-access journal Ferroptosis and Oxidative Stress highlights Z-nucleic acid-binding protein 1 (ZBP1) as an emerging innate immune sensor that converts genomic stress into potent antitumor immunity.

16 Jul 2026

New biological feedback loop helps the immune system attack colorectal cancers

A subset of cancers, known as microsatellite instability (MSI) and deficient DNA mismatch repair (dMMR) cancers, are more visible to the immune system than others.

16 Jul 2026

Experimental KRAS vaccine safely generates durable immune response against pancreatic cancer

Researchers at the Johns Hopkins Kimmel Cancer Center and its Skip Viragh Center for Pancreatic Cancer report that an experimental vaccine targeting mutant KRAS, one of the most common genetic drivers of pancreatic cancer, was safe and generated durable immune responses aimed at preventing the cancer in people at high risk.

16 Jul 2026